Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01395329 · ClinicalTrials.gov registry record · Phase 4
Nebivolol and the Endothelin (ET)-1 System
A Phase 4 study, sponsored by University of Colorado, Boulder.
- Completed
- Registry status
- Phase 4
- Development phase
- 42
- Enrollment target
NCT01395329: Completed Phase 4 study, sponsored by University of Colorado, Boulder.
NCT01395329 is a Phase 4 study that has completed, run by University of Colorado, Boulder. The registered enrollment target is 42 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01395329, a Phase 4 study, has completed, sponsored by University of Colorado, Boulder.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 42 participants
- Enrollment target
Study Summary
The investigators hypothesize that nebivolol will reduce ET-1-mediated vasoconstrictor tone in adult humans with elevated blood pressure to a greater extent than either metoprolol or placebo.
Interventions
- DRUG Placebo
- DRUG Nebivolol
- DRUG Metoprolol
- OTHER Forearm Blood Flow (FBF) response to BQ-123 (100 mol/min)
- OTHER FBF response to BQ-123 (100 nmol/min)+BQ-788(50 nmol/min)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2011-05 |
| Est. Completion | 2016-12 |
| Phase | Phase 4 |
What the finished NCT01395329 record still lists
NCT01395329 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01395329 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01395329 about?
NCT01395329 is a clinical study titled "Nebivolol and the Endothelin (ET)-1 System". The investigators hypothesize that nebivolol will reduce ET-1-mediated vasoconstrictor tone in adult humans with elevated blood pressure to a greater extent than either metoprolol or placebo.
What is the current status of trial NCT01395329?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 42 participants. The study started on 2011-05. Estimated completion is 2016-12.
What interventions are being tested in trial NCT01395329?
The interventions under investigation include: Placebo (DRUG), Nebivolol (DRUG), Metoprolol (DRUG), Forearm Blood Flow (FBF) response to BQ-123 (100 mol/min) (OTHER), FBF response to BQ-123 (100 nmol/min)+BQ-788(50 nmol/min) (OTHER).
Who is sponsoring clinical trial NCT01395329?
This trial is sponsored by University of Colorado, Boulder, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01395329's enrollment target sits among peer trials
42 1380th of 2000 higher than 611 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia